← American Pharmacists Association (APhA)
FDARulemakingFDA-2015-N-0030

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

RIN
—
Last modified
May 18, 2026
Comment window
closed 1442d ago
American Pharmacists Association (APhA) filings
1

Activity

American Pharmacists Association (APhA) filed 1 comment on this docket between Nov 6, 2025 and Nov 6, 2025. 27 other organizations filed here. The comment window closed 1442d ago.

What American Pharmacists Association (APhA) filed (1)

Nov 6, 2025· Comment from American Pharmacists Association (APhA)· FDA-2015-N-0030-207708

The American Pharmacists Association (APhA) writes to submit our concerns from APhA's listening session with FDA on May 22, 2025, regarding the current environment surrounding GLP-1 receptor agonists and outline recommendations to enhance patient safety. APhA thanks FDA for arranging and attending this listening session and collaboration in the future to implement these recommendations to improve patient safety. APhA is the only organization advancing the entire pharmacy profession. It represents pharmacists, student pharmacists, and pharmacy technicians in all practice settings, including—but not limited to—community pharmacies, hospitals, long-term care facilities, specialty pharmacies, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and government facilities. Our members strive to improve medication use, advance patient care, and enhance public health.

View on regulations.gov →

Abstract

Compounding of Human Drug Products

View on regulations.gov →

Co-filers (27)

See everyone who commented →
Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket (FDA) — American Pharmacists Association (APhA) | OpenPolis